Generated Narrative: StructureDefinition bcr-breast-tumour-supplement Name Flags Card. Type Description & Constraints <a href="StructureDefinition-bcr-breast-tumour-supplement-definitions.html#bcr-breast-tumour-supplement" title="Logical model of the breast-tumour-specific supplement to the standard cancer#xA;registration form (Bijlage 55, *vervolg 1*). Contains menopausal status,#xA;molecular markers (with separate values for tumour 1 and, when multifocal,#xA;tumour 2), and surgical / lymph node data.#xA;#xA;Source: Bijlage 55 (vervolg 1) of the RIZIV Verordening of 28 July 2003,#xA;amended 15 December 2025.">bcr-breast-tumour-supplement 0..* Base BCR Breast Tumour Supplement — Bijlage 55 vervolg 1 (Logical Model) #xD; menopausalStatus 0..1 code Menopausal status at diagnosis Binding: BCR Menopausal Status (required) #xD; molecularMarker 0..* BackboneElement Molecular marker result #xD; <a href="StructureDefinition-bcr-breast-tumour-supplement-definitions.html#bcr-breast-tumour-supplement.molecularMarker.marker" title="Molecular marker. Form-listed markers:#xA;ER (oestrogen receptor), PR (progesterone receptor),#xA;HER2-IHC (HER2 IHC score), HER2-IHC-ISH (combined HER2 status),#xA;BRCA1-2, CHEK2, PALB2, ATM, PIK3CA (PIKCA3 on the form),#xA;KI67 (Ki-67 before systemic therapy), OTHER (free-text marker name).">marker 1..1 code Marker Binding: BCR Molecular Marker (required) #xD; otherMarkerName 0..1 string Other marker name #xD; tumourIndex 1..1 unsignedInt Tumour index #xD; testDate 0..1 date Test date #xD; <a href="StructureDefinition-bcr-breast-tumour-supplement-definitions.html#bcr-breast-tumour-supplement.molecularMarker.result" title="Result of the marker. Permitted codings depend on the marker:#xA;- ER, PR: positief / gering positief / negatief.#xA;- HER2-IHC: 0 / 1+ / 2+ / 3+.#xA;- HER2-IHC-ISH: positief / HER2 low (provisional) / negatief.#xA;- BRCA1-2, CHEK2, PALB2, ATM, PIK3CA: niet getest / geen mutatie / somatische mutatie / kiembaanmutatie.#xA;- KI67: see `resultPercentage` (or `niet getest`).">result 0..1 CodeableConcept Result Binding: BCR Molecular Marker Result (union) (extensible) #xD; resultPercentage 0..1 decimal Result percentage #xD; surgeryPerformed 0..1 boolean Surgery performed #xD; maxPathDiameterInvasiveMm 0..1 decimal Max pathological diameter, invasive component, before systemic therapy (mm) #xD; maxPathDiameterInSituMm 0..1 decimal Max pathological diameter, in situ component, before systemic therapy (mm) #xD; minMarginDistanceInvasiveMm 0..1 decimal Min distance, invasive component to surgical margin (mm) #xD; minMarginDistanceInSituMm 0..1 decimal Min distance, in situ component to surgical margin (mm) #xD; lymphNodeAssessment 0..* BackboneElement Lymph node assessment #xD; location 1..1 code Node location Binding: BCR Lymph Node Location (required) #xD; examined 0..1 unsignedInt Number examined #xD; positive 0..1 unsignedInt Number positive #xD; assessmentDate 0..1 date Assessment date #xD; Documentation for this format
BCR Breast Tumour Supplement — Bijlage 55 vervolg 1 (Logical Model)
Logical model of the breast-tumour-specific supplement to the standard cancer registration form (Bijlage 55, *vervolg 1*). Contains menopausal status, molecular markers (with separate values for tumour 1 and, when multifocal, tumour 2), and surgical / lymph node data. Source: Bijlage 55 (vervolg 1) of the RIZIV Verordening of 28 July 2003, amended 15 December 2025.
Menopausal status. Codes: ja / nee / onduidelijk / niet gekend / niet van toepassing (mannelijke patiënt).
One molecular-marker measurement on tumour 1, or on tumour 2 in the case of multifocal disease.
All FHIR elements must have a @value or children
hasValue() or (children().count() > id.count())
Unique id for the element within a resource (for internal references). This may be any string value that does not contain spaces.
Extensions are always sliced by (at least) url
Additional content defined by implementations
May be used to represent additional information that is not part of the basic definition of the element. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension.
There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions. The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.
Must have either extensions or value[x], not both
exists(f:extension)!=exists(f:*[starts-with(local-name(.), "value")])
Extensions that cannot be ignored even if unrecognized
May be used to represent additional information that is not part of the basic definition of the element and that modifies the understanding of the element in which it is contained and/or the understanding of the containing element's descendants. Usually modifier elements provide negation or qualification. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension. Applications processing a resource are required to check for modifier extensions. Modifier extensions SHALL NOT change the meaning of any elements on Resource or DomainResource (including cannot change the meaning of modifierExtension itself).
Modifier extensions allow for extensions that *cannot* be safely ignored to be clearly distinguished from the vast majority of extensions which can be safely ignored. This promotes interoperability by eliminating the need for implementers to prohibit the presence of extensions. For further information, see the [definition of modifier extensions](http://hl7.org/fhir/R4/extensibility.html#modifierExtension).
Modifier extensions are expected to modify the meaning or interpretation of the element that contains them
Molecular marker. Form-listed markers: ER (oestrogen receptor), PR (progesterone receptor), HER2-IHC (HER2 IHC score), HER2-IHC-ISH (combined HER2 status), BRCA1-2, CHEK2, PALB2, ATM, PIK3CA (PIKCA3 on the form), KI67 (Ki-67 before systemic therapy), OTHER (free-text marker name).
Free-text marker name when `marker = OTHER`.
Tumour to which the result applies: 1 (primary tumour) or 2 (second tumour, only in multifocal disease).
Result of the marker. Permitted codings depend on the marker: - ER, PR: positief / gering positief / negatief. - HER2-IHC: 0 / 1+ / 2+ / 3+. - HER2-IHC-ISH: positief / HER2 low (provisional) / negatief. - BRCA1-2, CHEK2, PALB2, ATM, PIK3CA: niet getest / geen mutatie / somatische mutatie / kiembaanmutatie. - KI67: see `resultPercentage` (or `niet getest`).
Numeric percentage result. Used for Ki-67 (`marker = KI67`).
Indicates whether section 3 (surgical data) is in scope. When false or absent, the surgery fields below are not applicable.
Max pathological diameter, invasive component, before systemic therapy (mm)
Maximale pathologische doormeter invasieve component vóór systemische therapie.
Max pathological diameter, in situ component, before systemic therapy (mm)
Maximale pathologische doormeter in situ component vóór systemische therapie.
Min distance, invasive component to surgical margin (mm)
Minimale afstand van de invasieve component tot de snijrand.
Min distance, in situ component to surgical margin (mm)
Minimale afstand van de in situ component tot snijrand.
One row of the sentinel / axillary / other-nodes table.
Lymph node group. Codes: SENTINEL (Sentinelklieren), AXILLARY (Axillaire klieren), OTHER (Andere klieren).